RECISTResponse Evaluation Criteria in Solid Tumors (oncology review criteria)
References in periodicals archive ?
With this background, a descriptive study was aimed to determine the correlation between the WHO response criteria and RECIST response criteria in Locally Advanced Breast Cancer following Neoadjuvant chemotherapy.
2] Nonstandard abbreviations: MPS, massively parallel sequencing; cfDNA, cell-free DNA; RECIST, Responsive Evaluation Criteria in Solid Tumors.
Two-year OS rates for patients with nonprogressive disease per both criteria, progressive disease per RECIST vl.
The primary endpoint was CB, defined as remaining progression-free by RECIST and PSA after treatment for 12+ weeks.
The main feature of RECIST is that the size of lesions is based on a one-dimensional measurement within planes transverse to the axis of data acquisition.
The organisation offers quality reporting by radiologists experienced in RECIST (Response Evaluation Criteria In Solid Tumors) and WHO (World Health Organisation) measurement criteria.
All participants had biochemical-recurrent ovarian cancer (defined as a rise in CA 125 of at least twice the upper limit of normal with no evidence of disease by RECIST (Response Evaluation Criteria in Solid Tumors) 1.
Tumor response after 7 weeks, according to RECIST (Response Evaluation Criteria in Solid Tumors), showed a higher proportion of patients with non-progressive disease in the combination arm (60%, 65%, and 52%, respectively, for gemcitabine plus low, medium, and high doses of EndoTAG-1) than in the gemcitabine only arm (43%).
These results included 9 patients treated with the Recommended Phase 2 Dose of 8mg of which 4 achieved RECIST v1.
Secondary objectives include evaluating tumor response rate and duration of response by RECIST 1.
Preliminary overall efficacy included 10% complete response, 50% objective response, and 60% clinical benefit, with the highest responses observed in Stage IV M1c melanoma patients (all per RECIST 1.